TORVANTA
Other · S&P 500 · data as of 2026-10-05

SRPT stock analysis: SRPT

SRPT (SRPT) is an S&P 500 company in Other. It grades weakest on momentum and profitability.

The model's view of SRPT · subscribers

Where SRPT ranks among the 1,500 U.S. stocks the model scores each trading day, its expected return, the evidence for and against it, and whether the model portfolio holds it. The grades below describe the company's data; they are not the model's view.

See plans
What's happening with SRPT · updated 2026-10-05 · from prices and SEC filings

SRPT price performance

SRPT against the S&P 500, one year
-20%+0%+20%S&P 500 +18%SRPT -7%2025-09-292026-10-05
Year to date-18.7%S&P 500 +14.5% · behind by 33.2 pts
1 year-22.8%S&P 500 +17.0% · behind by 39.8 pts
3 years-85.6%S&P 500 +89.3% · behind by 174.8 pts
5 years-81.6%S&P 500 +91.3% · behind by 172.9 pts

Total returns with dividends reinvested.

SRPT factor grades

Each grade compares SRPT with the rest of its sector (A+ best, F worst); the numbers behind it are shown with the typical figure for its peers.

–ValueFCF yield 4.4% (industry 6.0%)
–GrowthRevenue growth -20% (industry +8%)
D-ProfitabilityOperating margin -7.3% (industry 9.6%)ROIC -6.3% (industry 10.1%)
D+Momentum12-month change -23%From 52-wk high -28%

SRPT in plain numbers

SRPT key statistics

SectorOther
Industryn/a
IndexS&P 500
Market value$1.8B
Revenue growth (y/y)-20%
Free-cash-flow yield4.4%
Dividend yieldn/a
Next earnings (expected)2026-11-02
Valuation measures
Market value$1.8B
Enterprise value$2.1B
Price / sales0.9x
Price / book1.2x
EV / revenue1.1x
Financial highlights
Revenue, last 12 months$2.0B
Net income, last 12 months-$266.1M
EPS, last 12 months (GAAP)$-2.90
Operating margin-7.3%
Net margin-13.5%
Return on equity-18.4%
Return on invested capital-6.3%
Cash$571.1M
Total debt$847.6M
Debt / equity0.55x
Free cash flow, last 12 months$81.8M
Current ratio4.42x

Company figures from its latest SEC filings; market value and returns from end-of-day prices.

SRPT earnings trends

Revenue vs earnings
-$447.5M-$149.4M$148.7M$446.8M$744.9MSep 2024 Revenue: $467.2MDec 2024 Revenue: $658.4MMar 2025 Revenue: $744.9MJun 2025 Revenue: $611.1MSep 2025 Revenue: $399.4MDec 2025 Revenue: $442.9MMar 2026 Revenue: $730.8MJun 2026 Revenue: $401.3MSep 2024 Net income: $33.6MDec 2024 Net income: $159.0MMar 2025 Net income: -$447.5MJun 2025 Net income: $196.9MSep 2025 Net income: -$179.9MDec 2025 Net income: -$412.2MMar 2026 Net income: $331.0MJun 2026 Net income: -$4.9MSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Net margin: 7.2%Net margin: 24.2%Net margin: -60.1%Net margin: 32.2%Net margin: -45.1%Net margin: -93.1%Net margin: 45.3%Net margin: -1.2%-93%-24%45%■ Revenue ■ Net income ━ Net margin
Earnings per share$-4.6$-2.7$-0.9$1.0$2.9Sep 2024 EPS (GAAP, diluted): $0.3Dec 2024 EPS (GAAP, diluted): $1.5Mar 2025 EPS (GAAP, diluted): $-4.6Jun 2025 EPS (GAAP, diluted): $1.9Sep 2025 EPS (GAAP, diluted): $-1.8Dec 2025 EPS (GAAP, diluted): $-3.9Mar 2026 EPS (GAAP, diluted): $2.9Jun 2026 EPS (GAAP, diluted): $-0.1Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026■ EPS (GAAP, diluted) Change from a year earlier: Sep 2025 -629% · Dec 2025 -362% · Jun 2026 -103%

From the company's 10-Q and 10-K filings with the SEC.

SRPT financials (from SEC filings)

Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue$701.9M$933.0M$1.2B$1.9B$2.2B
Net income-$418.8M-$703.5M-$536.0M$235.2M-$842.8M
EPS (GAAP)$-5.15$-8.03$-5.83$2.28$-8.44
Free cash flow-$481.7M-$356.2M-$577.1M-$342.7M-$307.5M

SRPT earnings history

ReportedEPS (GAAP)EPS y/yRevenue y/yStock vs S&P 500, 2 days
2026-08-05$-0.05-103%-34%+2.7%
2026-05-06$2.88n/a-2%-5.6%
2026-02-25$-3.93-362%-33%-7.7%
2026-01-12$-3.93-362%-33%-9.9%
2025-11-03$-1.80-629%-15%-31.5%
2025-07-16$1.89+2600%+68%+19.7%

About SRPT

HeadquartersCambridge, MA
Industry (SEC code)Pharmaceutical Preparations
Fiscal year endsDecember 31
Incorporated inDE
Listed onNasdaq
FormerlySarepta Therapeutics, Inc., AVI BIOPHARMA INC, ANTIVIRALS INC

From the company's SEC registration record.

Companies similar to SRPT

CompanyMarket valueP/ERevenue growthOperating margin12-month change
SRPT SRPT$1.8Bn/a-20%-7.3%-23%
HMN HMN$1.8B10.7x+6%n/a+6%compare
VSTS VSTS$1.9Bn/a-0%3.6%+177%compare
LMAT LMAT$1.9B28.4x+12%29.5%-7%compare
EPAC EPAC$1.8B20.4x+4%21.2%-13%
OLN OLN$1.9Bn/a+1%-1.6%-35%
PLAB PLAB$1.8B11.0x+1%22.5%+27%

All Other stock ratings

Frequently asked questions

Is SRPT stock a buy?

Torvanta does not tell individuals what to buy. Its grades for SRPT are shown above. Subscribers see the model's rank, expected return and whether the model portfolio holds it. This is research, not a recommendation.

When does SRPT report earnings next?

Based on its filing history, Torvanta expects SRPT to report around 2026-11-02.

How has SRPT performed against the S&P 500?

Over the past year SRPT returned -22.8%, against +17.0% for the S&P 500, dividends reinvested.

See the model's view

Subscribers get the model's rank and expected return for every covered company, the reasoning behind each, and the Torvanta model portfolio's trades each trading day, sized and explained, at three risk levels.

See plans Or get the free weekly newsletter

Torvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.

All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer